[go: up one dir, main page]

WO2023227669A3 - Nouvelles protéines d'édition d'acides nucléiques - Google Patents

Nouvelles protéines d'édition d'acides nucléiques Download PDF

Info

Publication number
WO2023227669A3
WO2023227669A3 PCT/EP2023/063933 EP2023063933W WO2023227669A3 WO 2023227669 A3 WO2023227669 A3 WO 2023227669A3 EP 2023063933 W EP2023063933 W EP 2023063933W WO 2023227669 A3 WO2023227669 A3 WO 2023227669A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
novel nucleic
novel
editing proteins
editing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/063933
Other languages
English (en)
Other versions
WO2023227669A2 (fr
Inventor
Tyson David BOWEN
Lila Herk RIEBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to JP2024569521A priority Critical patent/JP2025517515A/ja
Priority to EP23729980.5A priority patent/EP4532704A2/fr
Publication of WO2023227669A2 publication Critical patent/WO2023227669A2/fr
Publication of WO2023227669A3 publication Critical patent/WO2023227669A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux systèmes d'édition de bases comprenant un domaine de nucléase guidé par ARN et un nouveau domaine de cytidine désaminase. L'invention concerne également de nouveaux peptides de protection d'uracile utiles pour des applications d'édition de bases.
PCT/EP2023/063933 2022-05-26 2023-05-24 Nouvelles protéines d'édition d'acides nucléiques Ceased WO2023227669A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024569521A JP2025517515A (ja) 2022-05-26 2023-05-24 新規核酸編集タンパク質
EP23729980.5A EP4532704A2 (fr) 2022-05-26 2023-05-24 Nouvelles protéines d'édition d'acides nucléiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263346065P 2022-05-26 2022-05-26
US63/346,065 2022-05-26

Publications (2)

Publication Number Publication Date
WO2023227669A2 WO2023227669A2 (fr) 2023-11-30
WO2023227669A3 true WO2023227669A3 (fr) 2024-02-22

Family

ID=86760329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/063933 Ceased WO2023227669A2 (fr) 2022-05-26 2023-05-24 Nouvelles protéines d'édition d'acides nucléiques

Country Status (3)

Country Link
EP (1) EP4532704A2 (fr)
JP (1) JP2025517515A (fr)
WO (1) WO2023227669A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12454694B2 (en) 2018-09-07 2025-10-28 Beam Therapeutics Inc. Compositions and methods for improving base editing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081568A1 (fr) * 2018-10-15 2020-04-23 University Of Massachusetts Édition de base d'adn programmable par des protéines de fusion nme2cas9-désaminase
WO2022008466A1 (fr) * 2020-07-06 2022-01-13 Wageningen Universiteit Outils d'édition de bases
WO2022015969A1 (fr) * 2020-07-15 2022-01-20 LifeEDIT Therapeutics, Inc. Protéines stabilisant l'uracile et fragments actifs et variants de celles-ci et procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025673A1 (fr) 1992-06-04 1993-12-23 The Regents Of The University Of California Therapie genique in vivo a l'aide d'une sequence significative sans intron
CA2153593C (fr) 1993-01-26 2010-04-13 David B. Weiner Compositions et methodes pour l'introduction de materiel genetique dans des cellules
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6768550B2 (en) 2002-07-26 2004-07-27 Proterion Corporation Beam shifting surface plasmon resonance system and method
WO2017070633A2 (fr) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Protéines cas9 évoluées pour l'édition génétique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081568A1 (fr) * 2018-10-15 2020-04-23 University Of Massachusetts Édition de base d'adn programmable par des protéines de fusion nme2cas9-désaminase
WO2022008466A1 (fr) * 2020-07-06 2022-01-13 Wageningen Universiteit Outils d'édition de bases
WO2022015969A1 (fr) * 2020-07-15 2022-01-20 LifeEDIT Therapeutics, Inc. Protéines stabilisant l'uracile et fragments actifs et variants de celles-ci et procédés d'utilisation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 7 April 2016 (2016-04-07), YUAN Y: "Bacillus phage vB_BpuM-BpSp uracil-DNA glycosylase inhibitor", XP093076687, retrieved from EBI accession no. ALN97938 Database accession no. ALN97938 *
DATABASE EMBLWGS [online] 31 January 2021 (2021-01-31), HARRISON L H: "Serratia marcescens hypothetical protein", XP093076675, retrieved from EBI accession no. MBN5231334 Database accession no. MBN5231334.1 *
DATABASE Geneseq [online] 30 June 2022 (2022-06-30), "Cytidine deaminase (APG30130), SEQ ID 86.", XP093076574, retrieved from EBI accession no. GSP:BKO08826 Database accession no. BKO08826 *
DATABASE Geneseq [online] 30 March 2022 (2022-03-30), "Cytidine deaminase (APG30125), SEQ ID 81.", XP093115791, retrieved from EBI accession no. GSP:BKO08821 Database accession no. BKO08821 *
DATABASE TrEMBL [online] 31 July 2019 (2019-07-31), GOEKER M.: "Genomic Encyclopedia of Type Strains, Phase IV (KMG-IV): sequencing theRT most valuable type-strain genomes for metagenomic binning, comparativeRT biology and taxonomic classification", XP093115800, retrieved from UniProt accession no. A0A4V3BN72_9RHOO Database accession no. A0A4V3BN72 *
KOMOR ALEXIS C ET AL: "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 533, no. 7603, 19 May 2016 (2016-05-19), pages 420 - 424, XP037336614, ISSN: 0028-0836, DOI: 10.1038/NATURE17946 *
WANG H.-C. ET AL: "Staphylococcus aureus protein SAUGI acts as a uracil-DNA glycosylase inhibitor", NUCLEIC ACIDS RESEARCH, vol. 42, no. 2, 22 October 2013 (2013-10-22), GB, pages 1354 - 1364, XP055855618, ISSN: 0305-1048, DOI: 10.1093/nar/gkt964 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12454694B2 (en) 2018-09-07 2025-10-28 Beam Therapeutics Inc. Compositions and methods for improving base editing

Also Published As

Publication number Publication date
EP4532704A2 (fr) 2025-04-09
WO2023227669A2 (fr) 2023-11-30
JP2025517515A (ja) 2025-06-05

Similar Documents

Publication Publication Date Title
WO2018027078A8 (fr) Éditeurs de nucléobases d'adénosine et utilisations associées
GB2405406B (en) Viral vectors
EP4257696A3 (fr) Nouveaux systèmes et enzymes de ciblage d'adn crispr
WO2018151868A3 (fr) Protéines de fusion à domaine de liaison à l'albumine
PT1121382E (pt) Proteinas de fusao do interferao beta e as respectivas utilizacoes
IL134375A0 (en) System for protecting objects against shaped charges
EP1300468A3 (fr) Synthétase ARNt
AU6512299A (en) Gemini virus vectors for gene expression in plants
EP1288298A3 (fr) Synthétases-tRNA de Staphylococcus Aureus
AU2003254139A8 (en) H. pylori fucosyltransferases
PL353348A1 (en) Multiple cytokine-antibody complexes
EP1260587A3 (fr) Tyrosyl-tRNA-Synthetase
AU8067698A (en) Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
WO2023227669A3 (fr) Nouvelles protéines d'édition d'acides nucléiques
EP4021924A4 (fr) Nouveaux enzymes et systèmes ciblant l'adn crispr
EP3996738A4 (fr) Nouveaux enzymes et systèmes ciblant l'adn crispr
EP3983536A4 (fr) Nouveaux enzymes et systèmes ciblant l'adn crispr
WO2003066810A3 (fr) Virus d'immunodeficience bovine recombine sur la base de systeme de transfert de genes
MX9703702A (es) Adhesivos mejorados de laminacion basados en isocianato.
SG108864A1 (en) Laser gun and shooting system for the same
ATE532861T1 (de) Expressionsvektor
AU2024229193A1 (en) Engineered proteins and methods of use thereof
MX2022004433A (es) Conmutadores de acido ribonucleico (arn) eficientes y sistemas de expresion relacionados.
WO2024138202A3 (fr) Protéines effectrices, compositions, systèmes et procédés d'utilisation associés
WO2023220649A3 (fr) Compositions protéiques effectrices et leurs méthodes d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23729980

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024569521

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2023729980

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2023729980

Country of ref document: EP

Effective date: 20250102

WWP Wipo information: published in national office

Ref document number: 2023729980

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2023729980

Country of ref document: EP